Tofacitinib in ulcerative colitis

Archer, Thomas P.; Moran, Gordon W.; Ghosh, Subrata

Abstract

Cytokines orchestrate immune and inflammatory responses involved in the pathogenesis of ulcerative colitis (UC). Protein kinases are essential for signal transduction in eukaryotic cells. Janus kinases (JAKs) are a family of protein tyrosine kinases that play a pivotal role in cytokine receptor signaling. Indeed, a major subgroup of cytokines use Type I and II cytokine receptors which signal via the activation of JAKs. Tofacitinib is an oral JAK inhibitor that has been studied in autoimmune pathologies, including UC and rheumatoid arthritis with good overall efficacy and acceptable safety profile. This literature review was performed with the goal of summarizing the knowledge on JAK inhibitors in UC treatment.

Citation

Archer, T. P., Moran, G. W., & Ghosh, S. (2016). Tofacitinib in ulcerative colitis. Immunotherapy, 8(5), doi:10.2217/imt-2015-0031

• Journal Article Type: Article
• Acceptance Date: Mar 1, 2016
• Online Publication Date: May 3, 2016
• Publication Date: May 3, 2016
• Deposit Date: Dec 13, 2018
• Print ISSN: 1750-743X
• Publisher: Future Medicine
• Peer Reviewed: Peer Reviewed
• Volume: 8
• Issue: 5
• DOI: https://doi.org/10.2217/imt-2015-0031
• Public URL: https://nottingham-repository.worktribe.com/output/1413082
• Publisher URL: https://www.futuremedicine.com/doi/pdf/10.2217/imt-2015-0031